<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>770</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>12218139</PubmedId>
            <Abstract>Respiratory syncytial virus (RSV) causes severe respiratory diseases in infants and young children. Inappropriate immunity to the virus can lead to disease enhancement upon subsequent infection. In this study, we have characterized the antiviral immunity elicited by the recombinant Semliki Forest virus (SFV) encoding the RSV fusion (F) and attachment (G) protein, and compared with that induced by the immune-stimulating complex (ISCOM)-incorporated FG proteins. Antiviral immunity against RSV elicited nasally or parentally by either of the immunogen having divergent profiles could reduce lung RSV titers upon challenge. However, resistance to RSV without disease enhancement was only observed in those vaccinated with SFV recombinants via nasal route. Presence of postvaccination pulmonary IFN-gamma response to the H-2K(d)-restricted T cell epitope (F(85-93); KYKNAVTEL) was found to be associated with absence of enhanced pulmonary disease and goblet cell hyperplasia as well as reduced Th2-cytokine expression. This result demonstrates that the SFV recombinants can result in enhanced clearance of RSV without enhancing the RSV-associated disease, and underlines the importance in priming pulmonary MHC class I-restricted T cells when RSV FG-based vaccines are used.</Abstract>
            <ArticleYear>2002</ArticleYear>
            <ArticlePages>3208-16</ArticlePages>
            <ArticleTitle>Vaccination with recombinant alphavirus or immune-stimulating complex antigen against respiratory syncytial virus.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Margaret</ForeName>
                </Author>
                <Author>
                    <LastName>Hu</LastName>
                    <ForeName>Ke-Fei</ForeName>
                </Author>
                <Author>
                    <LastName>Rozell</LastName>
                    <ForeName>Björn</ForeName>
                </Author>
                <Author>
                    <LastName>Orvell</LastName>
                    <ForeName>Claes</ForeName>
                </Author>
                <Author>
                    <LastName>Morein</LastName>
                    <ForeName>Bror</ForeName>
                </Author>
                <Author>
                    <LastName>Liljeström</LastName>
                    <ForeName>Peter</ForeName>
                </Author>
            </Authors>
            <Affiliations>Microbiology and Tumorbiology Center, Karolinska Institutet, Stockholm, Sweden. Margaret.Chen@mtc.ki.se.</Affiliations>
            <ArticleChemicalList>Antibodies, Viral;Cytokines;ISCOMs;Immunodominant Epitopes;Respiratory Syncytial Virus Vaccines;Vaccines, Synthetic;Viral Fusion Proteins;Viral Proteins;Interferon-gamma</ArticleChemicalList>
            <ArticleMeshHeadingsList>Administration, Intranasal; Amino Acid Sequence; Animals; Antibodies, Viral(biosynthesis); Bronchoalveolar Lavage Fluid(cytology; immunology; virology); Cytokines(biosynthesis); ISCOMs(administration &amp; dosage; immunology); Immunodominant Epitopes(genetics; immunology); Immunophenotyping; Injections, Subcutaneous; Interferon-gamma(biosynthesis); Lung(immunology; metabolism; pathology); Mice; Mice, Inbred BALB C; Molecular Sequence Data; Respiratory Syncytial Virus Infections(immunology; pathology; virology); Respiratory Syncytial Virus Vaccines(administration &amp; dosage; immunology); Semliki forest virus(genetics; immunology); Spleen(immunology; metabolism; virology); Vaccines, Synthetic(administration &amp; dosage; genetics; immunology); Viral Fusion Proteins(administration &amp; dosage; genetics; immunology); Viral Proteins(administration &amp; dosage; immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>169</Volume>
                <Issue>6</Issue>
                <Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
                <Issn>0022-1767</Issn>
                <MedlineTa>J Immunol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>F85-93</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>KYKNAVTEL</LinearSequence>
                        <StartingPosition>85</StartingPosition>
                        <EndingPosition>93</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P03420.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>208893</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 3209</LocationOfData>
                <EpitopeId>34485</EpitopeId>
                <ReferenceStartingPosition>85</ReferenceStartingPosition>
                <ReferenceEndingPosition>93</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Major neutralizing activity has been reported against this Ag protein.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <TCellId>8016</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Age>6-10 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P03420.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>208893</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Fusion protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ISCOM</Adjuvant>
                                <Route>Intranasal</Route>
                                <DoseSchedule>2</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>ISCOM stands for immune-stimulating complex and has inbuilt adjuvant properties. Also s.c. route was used.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>124</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>F85-93</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KYKNAVTEL</LinearSequence>
                                        <StartingPosition>85</StartingPosition>
                                        <EndingPosition>93</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03420.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>208893</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>5</NumberOfSubjectsTested>
                            <AssayComments>Negative results were also obtained in the lungs of immunized animals with both intranasal administration and subcutaneous immunization.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <TCellId>8014</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Age>6-10 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P03420.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>208893</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Fusion protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>11033</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intranasal</Route>
                                <DoseSchedule>2</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Immunization was performed with recombinant SFV particles expressing either F protein or F and G proteins from RSV; s.c. route was also used.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>124</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>F85-93</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KYKNAVTEL</LinearSequence>
                                        <StartingPosition>85</StartingPosition>
                                        <EndingPosition>93</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03420.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>208893</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>5</NumberOfSubjectsTested>
                            <AssayComments>This is a previously established immunodominant epitope. Positive results were also obtained with a subcutaneous  immunization.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <TCellId>8015</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Age>6-10 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P03420.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>208893</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Fusion protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>11033</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intranasal</Route>
                                <DoseSchedule>2</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Immunization was performed with recombinant SFV particles expressing either F protein or F and G proteins from RSV; s.c. route was also used.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lung</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lung</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>124</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>F85-93</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KYKNAVTEL</LinearSequence>
                                        <StartingPosition>85</StartingPosition>
                                        <EndingPosition>93</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03420.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>208893</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>5</NumberOfSubjectsTested>
                            <AssayComments>Negative results were obtained with the use of a subcutaneous immunization.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>G183-197</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>WAICKRIPNKKPGKK</LinearSequence>
                        <StartingPosition>183</StartingPosition>
                        <EndingPosition>197</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P27026.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>208893</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 3209</LocationOfData>
                <EpitopeId>72231</EpitopeId>
                <ReferenceStartingPosition>183</ReferenceStartingPosition>
                <ReferenceEndingPosition>197</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>Also known as Attachment glycoprotein G. Major neutralizing activity was reported against this Ag protein.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <TCellId>8017</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Age>6-10 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P27026.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>208893</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Major surface glycoprotein G</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>11033</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intranasal</Route>
                                <DoseSchedule>2</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Immunization was performed with recombinant SFV particles expressing F and G proteins from RSV; s.c. route was also used. ISCOM (immune stimulating complex) was also used as carrier, with identical results.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lung</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lung</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>169</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>G183-197</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>WAICKRIPNKKPGKK</LinearSequence>
                                        <StartingPosition>183</StartingPosition>
                                        <EndingPosition>197</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P27026.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>208893</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>5</NumberOfSubjectsTested>
                            <AssayComments>Negative results were also obtained with splenocytes, either in this formulation or with ISCOM presentation of the source protein. Both intranasal administration and subcutaneous immunization gave negative results.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

